 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- ODM-208 / Orion Corp, Merck (MSD)
Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients (7.3.Q - Quimper Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1682;
P1/2
Conclusions Administration of ODM-208 to heavily pre-treated mCRPC patients with AR LBD mutation was highly effective in blocking the production of steroid hormones and showed promising antitumor activity. NCT03436485.
- ODM-208 / Orion Corp
Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). (Available On Demand; 240) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3665;
P1/2
Treatment with ODM-208 blocked all steroid hormone production and resulted in frequent ≥50% PSA reductions in this group of heavily pretreated mCRPC pts with various AR LBD mutations, some being long-lasting. cfDNA AR mutations are a promising predictive biomarker for ODM-208 efficacy.
- |||||| ODM-208 / Orion Corp, abiraterone acetate / Generic mfg.
1/3 Karim Fizazi @GustaveRoussy shares data on the CYP11A1 inhibitor, ODM-208 #GU22 @ASCO. How does it compare w/CYP17A1 blockade and abiraterone? Is differential activity due to FURTHER androgen inhibition or blocking OTHER #steroids? @PCF_Science (Twitter) - Feb 18, 2022
- ||||| ODM-208 / Orion Corp
P1 data: The #OncoAlertTopTweet 🚨Day 1⃣ #GU22 Dr. Fizazi CYPIDES trial of ODM-208 first-in-human, oral non-steroidal inhibitor of CYP11A1 with complete suppression of androgen levels & PSA response in 32% in pretreated #mCRPC adrenal insufficiency Tweet @jgong15 Best @weoncologists (Twitter) - Feb 17, 2022
- |||| ODM-208 / Orion Corp
The #OncoAlertTopTweet 🚨Day 1⃣ #GU22 A novel CYP11A1 inhibitor ODM-208 inhibits the entire steroid synthesis axis 👇with REMARKABLE activity in mCRPC #ProstateCancer with AR LBD mutations‼️ Tweet @neerajaiims Best @weoncologists (Twitter) - Feb 17, 2022
- |||||| ODM-208 / Orion Corp
Clinical: #GU22 @ASCO more data on safety and MOA of ODM-208, pan Steroid synthesis inhibitor, in mCRPC #ProstateCancer 👉 Expected deficiency in circulating steroids, requires supplementation @OncoAlert @PCF_Science (Twitter) - Feb 17, 2022
- |||||| ODM-208 / Orion Corp
#GU22 @ASCO A novel CYP11A1 inhibitor ODM-208 inhibits the entire steroid synthesis axis 👇and show REMARKABLE activity in mCRPC #ProstateCancer with AR LBD mutations👇. @OncoAlert @PCF_Science @urotoday #KarimFizazi (Twitter) - Feb 17, 2022
- |||||| ODM-208 / Orion Corp
P1 data: Dr. Fizazi Ph I CYPIDES trial of ODM-208 first-in-human, oral non-steroidal inhibitor of CYP11A1 with complete suppression of androgen levels and PSA response in 32% in pretreated #mCRPC adrenal insufficiency appears to be class effect for monitoring during advancement #GU22 (Twitter) - Feb 17, 2022
- ||||| ODM-208 / Orion Corp
Is there an advantage to blocking CYP11A1 over CYP17A1? Orion’s CYP11A1 inhib. certainly shows activity in Abi/Enz resistance! #GU22 @ASCO @TheEndoSociety Phase 1 results of the ODM-208 first-in-human phase 1-2 trial met CR prostate cancer. https://t.co/pYy0om9IxU (Twitter) - Feb 17, 2022
- ODM-208 / Orion Corp
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES). (In-Person & On Demand | Level 1, West Hall - A3) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_247;
P1/2
The phase 2 dose expansion part of CYPIDES is ongoing. ClinicalTrials.gov identifier: NCT03436485.
- ODM-208 / Orion Corp
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES). (Available On Demand) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_150;
P1/2
The phase 2 dose expansion part of CYPIDES is ongoing. ClinicalTrials.gov identifier: NCT03436485.
- || opevesostat (MK-5684) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: CYPIDES: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - May 10, 2021
P1/2, N=112, Recruiting, Sponsor: Orion Corporation, Orion Pharma
ClinicalTrials.gov identifier: NCT03436485. Trial completion date: May 2021 --> Oct 2022 | Trial primary completion date: May 2021 --> Oct 2022
- ODM-208 / Orion
[VIRTUAL] ODM-208, a novel, small-molecule CYP11A1 inhibitor, demonstrates strong inhibition of steroid biosynthesis and antitumor activity in castration-resistant prostate cancer (CRPC) model () - Mar 11, 2021 - Abstract #AACR2021AACR_455;
P1/2
In subjects with ODM-208 treatment all studied serum steroid hormones were decreased to under lower limit of quantification in the LC-MS/MS assays. These preclinical and clinical data suggest that ODM-208 has potential to provide clinical benefit to patients with treatment-resistant CRPC bearing altered steroid synthesis and/or mutated AR.
- ODM-208 / Orion
Safety profile and therapeutic efficacy of CYP11A1 inhibitor ODM-208 in cellular models and intact male dogs (Hall Bordeaux) - Feb 7, 2020 - Abstract #TAT2020TAT_50;
- |||| opevesostat (MK-5684) / Merck (MSD)
Enrollment open, Metastases: CYPIDES: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Apr 25, 2018
P1/2, N=156, Recruiting, Sponsor: Orion Corporation, Orion Pharma
These preclinical and clinical data suggest that ODM-208 has potential to provide clinical benefit to patients with treatment-resistant CRPC bearing altered steroid synthesis and/or mutated AR. Not yet recruiting --> Recruiting
- ||||| opevesostat (MK-5684) / Merck (MSD)
New P1/2 trial, Metastases: CYPIDES: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Feb 19, 2018
P1/2, N=156, Not yet recruiting, Sponsor: Orion Corporation, Orion Pharma